University of Colorado Hospital, Anschutz Outpatient Pavilion (AOP)

Aurora, Colorado 80045

1 studies enrolling now · 16 studies all time

What they study most

ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC, Adenoid Cystic Carcinoma, Advanced Cancers, Advanced Colorectal Cancer (Part 1), BRAF V600E-mutant Metastatic Colorectal Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Colorectal Adenocarcinomas, Colorectal Carcinoma, Endometrial Neoplasms, Esophageal Adenocarcinoma

Studies at this site

• A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. — Recruiting now
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors — Completed
• Study of PF-07265807 in Participants With Metastatic Solid Tumors. — Stopped early
• A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer — Completed
• Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers — Running, not enrolling
• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors — Stopped early
• A Study of PF-06873600 in People With Cancer — Stopped early
• Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. — Stopped early
• A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations — Completed
• Hepatic Impairment Study for Lorlatinib in Cancer Patients — Stopped early
• Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) — Completed
• A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) — Completed
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer — Completed
• Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC — Completed